2 completed, 1 active not recruiting, 1 withdrawn. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow IRX 2: new trials by email Literature Review of IRX 2 trials Research Report on IRX 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer Cyclophosphamide, IRX-2, Nivolumab - Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Phase 1 | Withdrawn | Emory University | 2020-07-01 | 2019-08-28 | |
| IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab - Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 8 | 2019-05-17 | 2026-08-21 |
| IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Pembrolizumab - Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 9 | 2019-04-30 | 2026-10-21 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors IRX 2, Nivolumab - Metastatic Cancer, Recurrent Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2019-02-13 | 2023-04-14 |
Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Neoplasm Metastasis (1) · Recurrence (1)
City of Hope Medical Center (2) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (4)
Daneng Li (1) · Joseph Chao (1) · Mihir Patel, MD (1) · Rohit Jain, MD, MPH (1)
P30CA033572 (1)